Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro Injection ...

Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long shortage of ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...

Complete Eli Lilly & Co. stock information by Barron's. View real-time LLY stock price and news, along with industry-best analysis.

Eli Lilly's recent 20% pullback is a buy-the-dip opportunity, as the market overreacted to mixed Orforglipron results. Blockbuster drugs Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Hilary Brueck Every time Hilary publishes a story, you’ll get an alert straight to your inbox!